[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Qiu W, Tong GX, Manolidis S, Close LG, Assaad AM, Su GH: Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer. Int J Cancer; 2008 Mar 1;122(5):1189-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.
  • We previously reported 4 PIK3CA mutations in 38 head and neck cancer samples, 3 of which were identified in 6 pharyngeal cancer samples.
  • To determine the mutation frequency of PIK3CA in pharyngeal cancer, we studied 24 additional cases of pharyngeal squamous cell carcinoma in this study.
  • Using both direct genomic DNA sequencing and novel mutant-enriched sequencing methods developed specifically for the 3 hot-spot mutations (H1047R, E545K and E452K) of PIK3CA, we detected 5 mutations of PIK3CA in the 24 pharyngeal cancers (20.8%).
  • We showed that the mutant-enriched sequencing method for the H1047R hot-spot mutation can identify the mutation in a mixed population of mutant and wild-type DNA sequences at 1:360 ratios.
  • These novel mutant-enriched sequencing methods allow the detection of the PIK3CA hot-spot mutations in clinical specimens which often contain limited tumor tissues (i.e., biopsy specimens).
  • The data further support that oncogenic PIK3CA may play a critical role in pharyngeal carcinogenesis, and the mutant-enriched sequencing methods for PIK3CA are sensitive and reliable ways to detect PIK3CA mutations in clinical samples.
  • Because PIK3CA and its pathway are potential targets for chemotherapy and radiation therapy, and frequent somatic mutation of PIK3CA has been identified in many human cancer types (e.g., breast cancer, colorectal cancer), the abilities to detect PIK3CA mutations with enhanced sensitivities have great potential impacts on target therapies for many cancer types.

  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • [Cites] Oncogene. 2000 May 25;19(23):2739-44 [10851074.001]
  • [Cites] Cancer Sci. 2006 Dec;97(12):1351-8 [17052259.001]
  • [Cites] N Engl J Med. 2001 Dec 27;345(26):1890-900 [11756581.001]
  • [Cites] J Pathol. 2002 Nov;198(3):335-42 [12375266.001]
  • [Cites] Science. 2004 Apr 23;304(5670):554 [15016963.001]
  • [Cites] Cancer Res. 1991 Jul 1;51(13):3497-502 [1675933.001]
  • [Cites] J Gastroenterol Hepatol. 1995 Jul-Aug;10(4):419-25 [8527708.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):99-102 [9916799.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7678-81 [15520168.001]
  • [Cites] Cell Cycle. 2004 Oct;3(10):1221-4 [15467468.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):802-7 [15647370.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):242-8 [15543611.001]
  • [Cites] Oncogene. 2005 Feb 17;24(8):1477-80 [15608678.001]
  • [Cites] Int J Cancer. 2005 May 1;114(5):806-16 [15609302.001]
  • [Cites] Expert Opin Ther Targets. 2005 Aug;9(4):769-90 [16083342.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10199-207 [16288007.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):921-9 [16341083.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):38-46 [16377414.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):1065-7 [16114017.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1441-6 [16533766.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3851-5 [16778113.001]
  • [Cites] Mol Pathol. 2000 Aug;53(4):165-72 [11040937.001]
  • (PMID = 17990317.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA095434-05; United States / NCI NIH HHS / CA / R01 CA109525-03; United States / NCI NIH HHS / CA / K01 CA095434-04; United States / NCI NIH HHS / CA / CA095434-04; United States / NCI NIH HHS / CA / CA109525-03; United States / NCI NIH HHS / CA / CA109525-04; United States / NCI NIH HHS / CA / R01 CA109525; United States / NCI NIH HHS / CA / R01 CA109525-04; United States / NCI NIH HHS / CA / K01 CA095434; United States / NCI NIH HHS / CA / CA095434; United States / NCI NIH HHS / CA / K01 CA095434-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA Primers; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human
  • [Other-IDs] NLM/ NIHMS150987; NLM/ PMC2792983
  •  go-up   go-down


2. Chung MK, Jeong HS, Park SG, Jang JY, Son YI, Choi JY, Hyun SH, Park K, Ahn MJ, Ahn YC, Kim HJ, Ko YH, Baek CH: Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res; 2009 Sep 15;15(18):5861-8
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer.
  • PURPOSE: This study aimed to investigate whether metabolic tumor volume (MTV) measured from [(18)F]-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) predicts short-term outcome to radiotherapy with or without chemotherapy and disease-free survival (DFS) in patients with pharyngeal cancers.
  • Short-term outcome was assessed using the treatment response evaluation by the Response Evaluation Criteria in Solid Tumors and recurrence events during follow-up (complete response/no recurrence or residual disease/recurrence).
  • A cutoff of 40 mL for the MTV was the best discriminative value for predicting treatment response.
  • By univariate analyses, patients with MTV > 40 mL showed a significantly lower number of complete response/no recurrence than did patients with MTV < or =40 mL [68.2% versus 87.8%; hazard ratio (HR), 3.34; 95% confidence interval (95% CI), 1.09-10.08; P = 0.03], as is the same in tumor-node-metastasis stage (87.5% for I-II versus 90% for III versus 63.8% for IV; P = 0.02).
  • The standardized uptake value for the primary tumor did not show any correlation with treatment outcome or DFS.
  • CONCLUSION: MTV has a potential value in predicting short-term outcome and DFS in patients with pharyngeal cancers.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorodeoxyglucose F18. Pharyngeal Neoplasms / diagnosis. Pharyngeal Neoplasms / therapy. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Treatment Outcome. Tumor Burden. Young Adult

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2010 Mar 15;16(6):1968; author reply 1968-9 [20215538.001]
  • (PMID = 19737951.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


3. Ogino I, Tsukuda M, Inoue T, Mikami Y, Itazawa T, Matsuda H, Koike I, Horiuchi C, Omura M, Taguchi T: Prognostic value of retropharyngeal node involvement in CT-based lymph node-positive pharyngeal cancer following radiotherapy. Anticancer Res; 2007 May-Jun;27(3B):1663-8
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of retropharyngeal node involvement in CT-based lymph node-positive pharyngeal cancer following radiotherapy.
  • PATIENTS AND METHODS: A total of 175 CT-based lymph node-positive patients with carcinoma of the head and neck were managed with definitive radiation therapy.
  • RPN involvement was identified only in pharyngeal cancer.
  • Fifty-two patients received induction chemotherapy and 58 received concurrent chemoradiotherapy.
  • Concurrent chemotherapy and RPN involvement significantly affected DFS on multivariate analysis in all pharyngeal cancer patients and non-nasopharyngeal cancer (NNP) patients.
  • RPN involvement, level IV involvement and concurrent chemotherapy also significantly affected locoregional control.
  • CONCLUSION: Our study confirmed a poor outcome was associated with RPN involvement in patients with CT-based node-positive pharyngeal cancer and NNP patients definitively treated by radiotherapy.
  • [MeSH-major] Lymph Nodes / radiography. Pharyngeal Neoplasms / radiography. Pharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17595793.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


Advertisement
4. Akins PT, Kerber CW, Pakbaz RS: Stenting of vertebral artery origin atherosclerosis in high-risk patients: bare or coated? A single-center consecutive case series. J Invasive Cardiol; 2008 Jan;20(1):14-20
MedlinePlus Health Information. consumer health - Atherosclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After treatment, all patients were monitored with ultrasound and angiography and were aggressively managed for vascular disease risk factors.
  • Drug-eluting stents (tacrolimus) were used in the last 5 cases.
  • Three of the 7 patients treated with uncoated stents developed restenosis.
  • One patient developed asymptomatic occlusion of her bare-metal stent.
  • One patient died from pharyngeal cancer at 8 months, and 1 from lung cancer at 17 months.
  • Placement of drug-eluting stents appears to reduce in-stent restenosis.
  • [MeSH-major] Atherosclerosis / therapy. Catheterization / methods. Coated Materials, Biocompatible. Stents. Vertebrobasilar Insufficiency / therapy
  • [MeSH-minor] Aged. Angiography / methods. Brain Ischemia / prevention & control. Cohort Studies. Drug-Eluting Stents. Female. Follow-Up Studies. Humans. Male. Middle Aged. Monitoring, Physiologic. Prospective Studies. Risk Assessment. Secondary Prevention. Sensitivity and Specificity. Treatment Outcome. Ultrasonography, Doppler. Vascular Patency. Vertebral Artery / physiopathology. Vertebral Artery / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18174613.001).
  • [ISSN] 1557-2501
  • [Journal-full-title] The Journal of invasive cardiology
  • [ISO-abbreviation] J Invasive Cardiol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coated Materials, Biocompatible
  •  go-up   go-down


5. Basić-Jukić N, Bubić-Filipi L, Prgomet D, Djanić Hadzibegović A, Bilić M, Kovac L, Kastelan Z, Pasini J, Mokos I, Basić-Koretić M, Kes P: Head and neck malignancies in Croatian renal transplant recipients. Bosn J Basic Med Sci; 2010 Apr;10 Suppl 1:S37-9
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Renal transplantation is associated with increased incidence of cancer.
  • We reviewed a large series of renal transplant recipients to determine the incidence and outcome of patients with malignant changes located at the head and neck.
  • Demographic data, localization and disease outcome were evaluated in patients who developed cancer.
  • Twenty one patients (1.7%) developed 27 head and neck malignancies.
  • The average time from transplantation to development of cancer was 56.8 months.
  • Of cutaneous malignancies, 88.9% were basal cell carcinoma; one patient had Merkell-cell carcinoma and one patient developed squamous cell carcinoma.
  • Six cases of basocellular skin cancer were recorded in one fair-skin patient.
  • Noncutaneous malignancies involved the oral cavity (2 cases of Kaposi's sarcoma and one pharyngeal cancer) and the thyroid gland in 3 patients each.
  • Two patients had post-transplant lymphoproliferative disorder occurring at the head and neck.
  • One patient had brain tumor.
  • Radical surgery, radiation, and/or chemotherapy were necessary in 33.3% of patients.
  • None of the patients died from cancer.
  • An increased incidence of cancer occurring in the head and neck was recorded.
  • Careful skin examination and oral examination is mandatory for discovering cancer before dissemination.
  • Sirolimus is safe alternative to calcineurin-based immunosuppression in patients who developed head and neck malignancies.
  • [MeSH-major] Head and Neck Neoplasms / complications. Head and Neck Neoplasms / etiology. Kidney Transplantation / methods. Renal Insufficiency / therapy
  • [MeSH-minor] Brain Neoplasms / complications. Croatia. Follow-Up Studies. Humans. Immunosuppression. Lymphoproliferative Disorders / etiology. Mouth Neoplasms / complications. Skin Neoplasms / complications. Thyroid Neoplasms / complications. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prilozi. 2009 Dec;30(2):175-84 [20087258.001]
  • [Cites] Nephrol Dial Transplant. 1995;10 Suppl 1:74-80 [7617285.001]
  • [Cites] Int J Cancer. 1996 May 29;66(5):591-3 [8647617.001]
  • [Cites] Arch Dermatol. 1972 Jan;105(1):107-10 [5009611.001]
  • [Cites] Semin Respir Infect. 1993 Sep;8(3):233-9 [8016484.001]
  • [Cites] Transplantation. 1993 Apr;55(4):742-7 [8475546.001]
  • [Cites] Acta Otolaryngol. 2008 Nov;128(11):1255-8 [18607958.001]
  • [Cites] Kidney Int. 2008 Jan;73(1):136 [18084267.001]
  • (PMID = 20433429.001).
  • [ISSN] 1840-4812
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


6. Klaassen I, Braakhuis BJ: Anticancer activity and mechanism of action of retinoids in oral and pharyngeal cancer. Oral Oncol; 2002 Sep;38(6):532-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anticancer activity and mechanism of action of retinoids in oral and pharyngeal cancer.
  • Epidemiological studies indicate that a low intake of vitamin A is associated with an increased risk of squamous cancer.
  • In vitro studies on cancer cells show that exposure to retinoids results in the inhibition of growth, by blocking the cell cycle or by inducing apoptosis.
  • With respect to the clinical efficacy of retinoids some positive effects have been observed in early stage oral and oropharyngeal cancer.
  • Administration of retinoids has been shown to elicit responses in leukoplakia, a premalignant lesion of the oral mucosa that frequently develops into invasive cancer.
  • Furthermore, it has been possible with a retinoid, 13-cis-retinoic acid, to delay or inhibit the development of second primary tumors in patients who have been curatively treated for a first primary tumor in the oral cavity or oropharynx.
  • Because of the short duration of the response, the intrinsic resistance to retinoids and the toxic side effects, the treatment with this class of compounds has not become a standard therapy.
  • This knowledge can be used to develop novel tumor-selective strategies.
  • This review gives an update on the role of retinoids in oral and oropharyngeal cancer and their precursor lesions.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Mouth Neoplasms / prevention & control. Pharyngeal Neoplasms / prevention & control. Retinoids / therapeutic use
  • [MeSH-minor] Humans. Leukoplakia, Oral / drug therapy. Neoplasms, Second Primary / prevention & control

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12167430.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Retinoids
  • [Number-of-references] 107
  •  go-up   go-down


7. Kohno N: The role of chemotherapy for advanced oro and hypopharyngeal cancer. Auris Nasus Larynx; 2004 Jun;31(2):113-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of chemotherapy for advanced oro and hypopharyngeal cancer.
  • Although important progress continuous to be made in the treatment of oro and hypopharyngeal cancer, the 5-year survival rate for all this disease has remained at less than 30% for the past 30 years.
  • In the early 1980s, chemotherapy was introduced with high expectation of reducing in the incidence of distant metastases and increasing the possibility of local control.
  • This article explores the use of chemotherapy in the treatment of advanced pharyngeal cancer.
  • Thus, the efficacy of chemotherapy are reviewed and treatment options for advanced pharyngeal cancer are made.
  • In these cases, the possibility of instituting adjuvant chemotherapy with an active treatment regimen may be taken into account depending on the condition of the patient and the tumor.
  • Patients with surgically resectable tumors are given 1-2 cycles of induction chemotherapy.
  • Cases who respond to the induction chemotherapy are subsequently given concurrent chemoradiotherapy.
  • The cases who do not respond to the induction chemotherapy are treated with radical surgery.
  • Patients with unresectable carcinoma are given concurrent chemoradiotherapy because local treatment should be performed in such patients as early as possible.
  • In principle, concurrent regimens should be supplemented with adjuvant chemotherapy in all cases.
  • This is particularly required for those with advanced N-stage patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Hypopharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15121218.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 35
  •  go-up   go-down


8. Barasch A, Epstein JB, Foong WC, Clayman L: Intralesional chemotherapy for head and neck carcinoma: a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2004 Mar;97(3):307-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intralesional chemotherapy for head and neck carcinoma: a review of the literature.
  • In the last decade chemotherapy has gained widespread acceptance in the treatment of oral and pharyngeal cancer.
  • Current standard treatment for advanced lesions consists of concomitant radiation and chemotherapy.
  • This approach has provided marginal improvement of prognosis for Stage III-IV disease.
  • Recent studies have explored the idea that locally delivered cytotoxic drugs could further improve prognosis in this patient population.
  • We review this literature with the objective of popularizing these data and suggesting future directions for treatment and clinical research for head and neck cancer.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Humans. Infusions, Intra-Arterial. Injections, Intralesional. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15024351.001).
  • [ISSN] 1079-2104
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 35
  •  go-up   go-down


11. Li LB, Luo RC, Liao WJ, Zhang MJ, Luo YL, Miao JX: Clinical study of Photofrin photodynamic therapy for the treatment of relapse nasopharyngeal carcinoma. Photodiagnosis Photodyn Ther; 2006 Dec;3(4):266-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical study of Photofrin photodynamic therapy for the treatment of relapse nasopharyngeal carcinoma.
  • OBJECTIVES: To evaluate the clinical response and adverse effects of Photofrin photodynamic therapy (PDT) in patients with relapse nasal pharyngeal cancer.
  • METHODS: Thirty patients with relapse nasal pharyngeal cancer were randomly divided into PDT group and chemotherapy group.
  • Two days after PDT the necrotic tissues were removed and newly identified sites were subject to another round of light irradiation.
  • In chemotherapy group, the routine cisplatin and 5-fluorouracil (DDP/5-FU) remedy was used.
  • RESULTS: The local response and nasal cavity obstruction remission rate in PDT group were better than that in chemotherapy group.
  • CONCLUSION: This pilot study suggests that Photofrin PDT is effective and safe in treatment of advanced nasal pharyngeal cancer and management of nasal obstruction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25046991.001).
  • [ISSN] 1572-1000
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


12. Kowalczuk A, Wiecek A, Franek E, Kokot F: [Plasma concentration of leptin, neuropeptide Y and tumor necrosis factor alpha in patients with cancers, before and after radio- and chemotherapy]. Pol Arch Med Wewn; 2001 Aug;106(2):657-68
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Plasma concentration of leptin, neuropeptide Y and tumor necrosis factor alpha in patients with cancers, before and after radio- and chemotherapy].
  • In patients with cancers progressive reduction of body mass is frequently recent.
  • Pathogenesis of cachexia in patients with cancer is multifactorial.
  • Such factors as cytokines, peptides relieved by tumor mass and different forms of treatment as radio or chemotherapy may play a major role in the pathogenesis of cachexia in patients with cancer.
  • The aim of this study was to assess the relationship between body fat and lean mass and plasma leptin, NPY and TNF concentrations in patients with cancer of oral cavity and pharynx, cancer of larynx and non-Hodgkin lymphoma (NIL).
  • 30 patients (10 with cancer of oral cavity and pharynx, 10 with cancer of larynx and 10 with non-Hodgkin lymphoma) were enrolled into this study.
  • Mean age of all cancer patients was 50 +/- 2.9 years (from 18 to 76 years).
  • The control group consisted of 29 healthy subjects with a means age 48 +/- 3.5 years (from 18 to 75 years), properly chosen according to the body weight, BMI, gender and age as above mentioned groups of patients with cancer.
  • In control and study groups body fat and not-fat mass was assessed before and after treatment using the bioelectrical impedance method.
  • Before oncological therapy patients with cancer did not differ from healthy subject with regard to body weight and body mass index.
  • After treatment significant: decrease of body weight, body fat mass and BMI was observed.
  • Serum leptin, NPY and TNF concentrations were analysed in healthy subjects and patients with cancer before and after treatment.
  • Before oncological treatment significantly lower serum leptin concentration in comparison to leptinaemia in control group was found.
  • In contrast to serum leptin, NPY serum concentration was similar in patients with cancer and in control subjects.
  • Serum concentration of TNF was significantly higher in patients with cancer in comparison to subjects of control group.
  • After oncological treatment, serum leptin and NPY concentration did not change significantly.
  • In contrast, serum TNF concentration decreased significantly after oncological therapy.
  • From the results obtained in this study we can conclude, that in patients with cancer secretion of leptin is decreased in relation to body fat mass.
  • However, contribution of this hormone to pathogenesis of cancer induced anorexia seems not to proven.
  • After this oncological treatment the relationship between serum leptin concentration and body mass is no longer significant.
  • [MeSH-major] Cachexia / blood. Head and Neck Neoplasms / blood. Head and Neck Neoplasms / therapy. Leptin / blood. Lymphoma, Non-Hodgkin / blood. Lymphoma, Non-Hodgkin / therapy. Neuropeptide Y / blood. Tumor Necrosis Factor-alpha / metabolism
  • [MeSH-minor] Adult. Aged. Body Mass Index. Case-Control Studies. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11926139.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Leptin; 0 / Neuropeptide Y; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


13. Magné N, Pivot X, Bensadoun RJ, Guardiola E, Poissonnet G, Dassonville O, Francoual M, Formento JL, Demard F, Schneider M, Milano G: The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy. Eur J Cancer; 2001 Nov;37(17):2169-77
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy.
  • The aim of this study was to analyse prognostic factors for time to treatment failure (TTF) and overall survival (OS) in patients with unresectable cancer of the pharynx.
  • A twice daily (b.i.d.) radiotherapy with concomitant cisplatin-5-fluorouracil chemotherapy was administered to 77 consecutive patients (68 males, 9 females; median age: 56 years).
  • The studied factors were: age, gender, tumour differentiation, tumour volume, initial hemoglobin level, karnofsky index (KI), primary tumour location, T, N, epidermal growth factor receptor (EGFR) level in the tumour (fmol/mg protein).
  • In order to select subgroups with different outcomes, a stratification of patients was performed based on the EGFR value: patients with tumour EGFR levels <35 fmol/mg protein, between 35 and 275 fmol/mg protein and >275 fmol/mg protein had 95%, 51% and 16% 3 year OS rates, respectively (log rank test; P=0.0001).
  • Interestingly, for patients exhibiting a complete response (CR) after concomitant b.i.d. chemo-radiotherapy, patients with EGFR levels <35 fmol/mg protein were all alive at 3 years; in contrast, there was only 70 and 13% 3 year survival rates for patients with EGFR tumour levels between 35 and 275 fmol/mg protein and above 275 fmol/mg protein, respectively.
  • EGFR determination appears to be a powerful prognostic parameter in unresectable pharyngeal cancer patients treated by concomitant chemo-radiotherapy.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / metabolism. Pharyngeal Neoplasms / metabolism. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Logistic Models. Male. Middle Aged. Neoplasm Proteins / metabolism. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11677103.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


14. Arnold DJ, Goodwin WJ, Weed DT, Civantos FJ: Treatment of recurrent and advanced stage squamous cell carcinoma of the head and neck. Semin Radiat Oncol; 2004 Apr;14(2):190-5
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent and advanced stage squamous cell carcinoma of the head and neck.
  • Despite advances in our ability to safely treat patients with recurrent cancer of the upper aerodigestive tract, outcomes for retreatment are generally poor and the first chance to cure these patients remains the best chance.
  • Thorough knowledge of the outlook and options for patients with recurrent disease is also of significance in choosing therapy for patients with newly diagnosed disease.
  • This is especially true for newly diagnosed patients making the choice between surgery and nonsurgical ("organ-sparing") options, who need to know the outlook for salvage surgery, should they recur after radiation with or without concomitant chemotherapy.
  • Unfortunately, the results of surgical salvage are generally poor for patients with advanced stage recurrence and for those who recur after treatment of advanced disease.
  • Surgical salvage is most effective for patients with recurrent laryngeal cancer, least effective for recurrent cancer of the pharynx, and is intermediate for recurrence in the oral cavity.
  • Patients choosing nonsurgical treatment for newly diagnosed cancer of the pharynx cannot rely on salvage surgery in the event of recurrence.
  • Reirraditation for patients who have failed initial treatment that included radiation therapy has been used at a number of institutions with some success.
  • Experience using reirradiation with or without concomitant chemotherapy continues to evolve.
  • Palliative chemotherapy is an option for most patients, but response rates are generally poor and of short duration, after failure of initial treatment that includes radiation therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Humans. Retreatment / methods. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15095264.001).
  • [ISSN] 1053-4296
  • [Journal-full-title] Seminars in radiation oncology
  • [ISO-abbreviation] Semin Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


15. Banga R, Ramsden J, Cox G: Recurrent squamous cell carcinoma in the neopharynx treated successfully with topical 5-fluorouracil. J Laryngol Otol; 2005 May;119(5):403-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the first reported case of a squamous cell carcinoma recurrence on a reconstructed flap in the pharynx treated successfully with topical chemotherapy.
  • The patient, treated for a pharyngeal cancer with resection and reconstruction with a free radial forearm flap, and post-operative radiotherapy, developed a tumour on the flap more than two years after surgery.
  • This was treated with 5-fluorouracil paste placed in the pharynx, with resolution of the tumour.
  • The patient was alive and well more than 28 months after this treatment, with no sign of disease recurrence.
  • Topical chemotherapy for treatment of oral cancer is well described for early disease, but we show that it may be a useful treatment in recurrent disease in selected patients.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Fluorouracil / administration & dosage. Pharyngeal Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Aged. Humans. Male. Neoplasm Recurrence, Local. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15949109.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


16. Bjordal K, Ahlner-Elmqvist M, Hammerlid E, Boysen M, Evensen JF, Biörklund A, Jannert M, Westin T, Kaasa S: A prospective study of quality of life in head and neck cancer patients. Part II: Longitudinal data. Laryngoscope; 2001 Aug;111(8):1440-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of quality of life in head and neck cancer patients. Part II: Longitudinal data.
  • OBJECTIVES: To evaluate the health-related quality of life (HRQL) of patients with head and neck cancer during and after treatment with radiotherapy, surgery, and chemotherapy.
  • Health-related quality of life was assessed at baseline and at 1, 2, 3, 6, and 12 months after start of treatment by means of the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire and the EORTC head and neck cancer-specific questionnaire.
  • Three hundred fifty-seven patients with cancer in the oral cavity, pharynx, larynx, nose, sinuses, and salivary glands and neck node metastases from unknown primaries filled in the questionnaires at baseline.
  • The general trend was that HRQL deteriorated significantly during treatment, followed by a slow recovery until the 12-month follow-up with few exceptions (senses, dry mouth, and sexuality).
  • The patients with pharyngeal cancer in general reported worse HRQL compared with the other groups and did not reach pretreatment values in several domains.
  • Stage was also an important factor for HRQL in patients with head and neck cancer.
  • CONCLUSION: Detailed knowledge about the differences between groups and changes over time may aid us in the communication with patients and in the design of intervention studies focusing on improvement of the support and rehabilitation of patients with head and neck cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Laryngeal Neoplasms. Lymphatic Metastasis. Male. Middle Aged. Mouth Neoplasms. Pharyngeal Neoplasms. Prospective Studies

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11568582.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


17. Abouzeid WM, Mokhtar SA, Mahdy NH, El Kwsky FS: Quality of life of patients with oral and pharyngeal malignancies. J Egypt Public Health Assoc; 2009;84(3-4):299-329

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life of patients with oral and pharyngeal malignancies.
  • The target population was cases of oral and pharyngeal cancer in Alexandria and El Behira regions.
  • Data about quality of life (QoL) were collected through interviewing 171 subjects using the Arabic version of "Functional Living Interview Questionnaire for Cancer" (FLIC).
  • Stage categories showed significant indirect correlation with QoL scores.
  • The best QoL according to total or psychological mean scores was recorded for pharyngeal-otherwise (pharyngeal of a mysterious origin) or lip cases, while the worst were for the floor of the mouth.
  • According to treatment; surgery showed the best QoL, while chemotherapy showed the worst.
  • All those treatment complications showed significant associations with dichotomous leveling of QoL.
  • Logistic regression showed that stage, late surgical complications, and response to treatment were the most important predictors of QoL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19889358.001).
  • [ISSN] 0013-2446
  • [Journal-full-title] The Journal of the Egyptian Public Health Association
  • [ISO-abbreviation] J Egypt Public Health Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


18. Büntzel J, Glatzel M, Kuttner K, Weinaug R, Fröhlich D: Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Semin Radiat Oncol; 2002 Jan;12(1 Suppl 1):4-13
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer.
  • The authors discuss the results of 3 studies of their group reflecting the possible role of amifostine in simultaneous radiochemotherapy (RCT) of advanced head and neck cancer.
  • A control group (n = 14) received simultaneous RCT of the head and neck region with an irradiation dose of 60 Gy and 2 cycles of carboplatin (700 mg/m(2) cumulative dose).
  • Twenty-five patients received the same basic therapy and an additional 500-mg dose of amifostine before each chemotherapy.
  • In a controlled intensification trial (1997 through 1999), the authors included 76 consecutive patients (69 men, 7 women) with pharyngeal cancer (oropharynx, n = 33; hypopharynx, n = 43).
  • All patients received a conventional radiotherapy (2-Gy single dose, daily fractionation) up to doses of 60 Gy and an additional 10 Gy as a boost in the tumor-infiltrated region.
  • If the tumor volume was less than 20 cm(3), we observed an increased 1-year overall survival rate (91% v 71%) and time to progression (17 months v 10 months).
  • If the tumor volume was greater than 20 cm(3), we observed comparable treatment results in both groups (1-year survival rate, 60% v 61%; time to progression, 13 months v 12 months).
  • All patients were treated by surgery or radio(chemo)therapy because of an advanced head and neck cancer.
  • A total of 218 of 531 patients received the antineoplastic therapy without cytoprotection.
  • Amifostine could be integrated in simultaneous radiochemotherapy of advanced head and neck cancer patients.
  • Selective cytoprotection could decrease the main acute toxicities (mucositis, xerostomia, dysphagia) as well as late side effects (xerostomia, loss of taste, fibrosis) of this form of combined treatment.
  • The enhanced therapeutic index may be changed into a prognostic benefit for selected patients with unresectable tumors, if the volume is smaller than 20 cm(3).
  • [MeSH-major] Amifostine / therapeutic use. Carcinoma, Squamous Cell / radiotherapy. Pharyngeal Neoplasms / radiotherapy. Radiation-Protective Agents / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carboplatin / therapeutic use. Combined Modality Therapy. Edema / etiology. Esophageal Stenosis / etiology. Female. Fibrosis. Follow-Up Studies. Humans. Male. Middle Aged. Radiation Injuries / pathology. Radiotherapy Dosage. Taste Disorders / etiology. Xerostomia / etiology

  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • (PMID = 11917277.001).
  • [ISSN] 1053-4296
  • [Journal-full-title] Seminars in radiation oncology
  • [ISO-abbreviation] Semin Radiat Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Protective Agents; BG3F62OND5 / Carboplatin; M487QF2F4V / Amifostine
  •  go-up   go-down


19. Naim R, Chang RC, Schultz J, Hormann K: Chemopreventive alteration of the cell-cell adhesion in head and neck squamous cell cancer. Oncol Rep; 2006 Aug;16(2):273-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemopreventive alteration of the cell-cell adhesion in head and neck squamous cell cancer.
  • Approximately 310,000 new cases of oral and pharynx cancer account for a major cause of neoplasm related morbidity and mortality world-wide.
  • The vast majority of head and neck cancer is squamous cell carcinoma.
  • The major adhesion-proteins involved in the development and maintenance of all solid tissue are the Cadherins.
  • Downregulation of Cadherins and catenins is frequently observed in many types of human cancer.
  • Sulindac sulfone is one of the new therapeutic apoptotic agents that show promise in the treatment of cancer.
  • In this study, we incubated sulindac sulfone with a head and neck cancer cell line and investigated the outcome of E-Cadherin.
  • Sulindac sulfone resulted in an increase of E-Cadherin content in the head and neck squamous cell cancer cell line after 48 h of incubation; however, the reactivity was restricted to the adherent junctions.
  • ELISA also depicted significant rising levels of E-Cadherin.
  • However, in epithelial cancer cells, the Cadherin-catenin complex serves as a target for the chemopreventive agent, sulindac sulfone.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cadherins / metabolism. Carcinoma, Squamous Cell / drug therapy. Cell Adhesion. Head and Neck Neoplasms / drug therapy. Sulindac / analogs & derivatives
  • [MeSH-minor] 3',5'-Cyclic-GMP Phosphodiesterases / antagonists & inhibitors. Apoptosis. Cyclic GMP / analysis. Cyclic GMP / metabolism. Humans. Immunohistochemistry. Protein Kinase C / analysis. Protein Kinase C / metabolism. Tumor Cells, Cultured. Up-Regulation. beta Catenin / analysis. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16820902.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cadherins; 0 / beta Catenin; 184SNS8VUH / Sulindac; EC 2.7.11.13 / Protein Kinase C; EC 3.1.4.35 / 3',5'-Cyclic-GMP Phosphodiesterases; H2D2X058MU / Cyclic GMP; K619IIG2R9 / sulindac sulfone
  •  go-up   go-down


20. Lang K, Sussman M, Friedman M, Su J, Kan HJ, Mauro D, Tafesse E, Menzin J: Incidence and costs of treatment-related complications among patients with advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg; 2009 Jun;135(6):582-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and costs of treatment-related complications among patients with advanced squamous cell carcinoma of the head and neck.
  • PATIENTS: The study included patients with ASCCHN and an indication of a secondary malignant neoplasm (both identified based on International Classification of Diseases, Ninth Revision, Clinical Modification, diagnosis codes), 124 of whom were treated with radiotherapy alone and 77 of whom were treated with chemoradiotherapy (including 53 with cisplatin plus radiotherapy, 26 with carboplatin plus radiotherapy, and 2 with cisplatin and carboplatin plus radiotherapy).
  • The patients were assigned to 1 of 2 cohorts based on treatment type-radiotherapy only and platinum-based chemoradiotherapy-and were followed up for 6 months.
  • MAIN OUTCOME MEASURES: Incidence and costs of treatment-related complications associated with chemotherapy in ASCCHN.
  • RESULTS: We found significantly (P < .001) higher rates of treatment-related complications among patients receiving chemoradiotherapy (86%) than among patients receiving only radiotherapy (51%).
  • The mean per-patient costs associated with treatment-related complications were approximately $10 000 higher among patients who received chemoradiotherapy than among those treated with radiotherapy alone (P < .001).
  • CONCLUSIONS: Our study results suggest that the attributable incidence and costs of treatment-related complications associated with chemotherapy in ASCCHN are substantial.
  • The emergence of safer treatments may have the advantage of alleviating this cost burden.
  • [MeSH-major] Carcinoma, Squamous Cell / economics. Carcinoma, Squamous Cell / therapy. Cost of Illness. Head and Neck Neoplasms / economics. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Carboplatin / adverse effects. Cisplatin / adverse effects. Combined Modality Therapy. Databases, Factual. Drug Therapy / economics. Drug-Related Side Effects and Adverse Reactions. Female. Hospitalization. Humans. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / economics. Laryngeal Neoplasms / radiotherapy. Male. Middle Aged. Pharyngeal Neoplasms / drug therapy. Pharyngeal Neoplasms / economics. Pharyngeal Neoplasms / radiotherapy. Postoperative Complications / economics. Radiation-Sensitizing Agents / adverse effects. Radiotherapy / adverse effects. Radiotherapy / economics. Retrospective Studies. Tongue Neoplasms / drug therapy. Tongue Neoplasms / economics. Tongue Neoplasms / radiotherapy. United States

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19528407.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Sensitizing Agents; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


21. Li CQ, Guo ZM, Liu WW, Zhang Q, Yang AK, Yang L: [Clinical analysis of myoepithelial carcinoma of head and neck]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Feb;45(2):124-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate clinical feature, diagnosis, treatment and prognosis of myoepithelial carcinoma (MC) in the head and neck.
  • METHODS: Clinical data of 11 patients which were confirmed by pathology and immunohistochemistry in Cancer Center, Sun Yat-sen University from Jan.
  • There were 5 cases in parotid gland, 1 in hard palate, 1 in maxillary sinus, 1 in pharyngeal recess, 1 in bucca cavioris, 1 in scalp, and 1 in gingiva.
  • The median age at diagnosis was 37 years (range: 14 - 60 years).
  • RESULTS: All cases were operated, 4 underwent surgery alone, 2 underwent surgery plus adjuvant radiotherapy, 2 received surgery plus adjuvant chemotherapy, 3 underwent surgery plus adjuvant chemoradiation.
  • There was spindle cell type in 5 cases, clear cell type, plasmacytoid cell type in 2 cases, epithelioid cell type, mixed type in 1 case.
  • The median follow-up time was 40 months.
  • AS to the last follow-up time, 8 patients died.
  • CONCLUSIONS: The characteristics of the tumor were rapidly enlarging, invading the surrounding regions, high rates of lymph node metastasis, high rates of distance metastasis.
  • MC was a sort of malignant tumor.
  • Chemotherapy and radiotherapy may be effective after operation.
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Myoepithelial carcinoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20398508.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


22. Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, Molinolo AA, Gutkind JS: Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res; 2005 Nov 1;65(21):9953-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Emerging knowledge on how the dysregulated function of signaling networks contributes to the malignant growth of squamous cell carcinoma of the head and neck (HNSCC) can now be exploited to identify novel mechanism-based anticancer treatments.
  • In this regard, we have observed that persistent activation of the serine/threonine kinase Akt is a frequent event in HNSCC, and that blockade of its upstream kinase, 3'-phosphoinositide-dependent kinase 1, potently inhibits tumor cell growth.
  • Furthermore, we observed that rapamycin displays a potent antitumor effect in vivo, as it inhibits DNA synthesis and induces the apoptotic death of HNSCC cells, ultimately resulting in tumor regression.
  • These findings identify the Akt-mTOR pathway as a potential therapeutic target for HNSCC, and may provide the rationale for the early clinical evaluation of rapamycin and its analogues in patients with HNSCC.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / enzymology. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / enzymology. Protein Kinases / metabolism. Sirolimus / pharmacology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. DNA, Neoplasm / biosynthesis. Female. Humans. Mice. Mice, Nude. Phosphatidylinositol 3-Kinases / metabolism. Phosphorylation. Proto-Oncogene Proteins c-akt / metabolism. Ribosomal Protein S6 Kinases, 70-kDa / metabolism. Signal Transduction / drug effects. TOR Serine-Threonine Kinases. Xenograft Model Antitumor Assays


23. Cianni R, Urigo C, Notarianni E, Saltarelli A, D'Agostini A, Iozzino M, Dornbusch T, Cortesi E: Radioembolisation using yttrium 90 (Y-90) in patients affected by unresectable hepatic metastases. Radiol Med; 2010 Jun;115(4):619-33
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: This study was done to evaluate the effectiveness of radioembolisation of liver metastases with yttrium 90 (Y-90) in patients with no response to chemotherapy.
  • MATERIALS AND METHODS: From February 2005 to January 2008, we treated 110 patients affected by liver metastatic disease from colorectal, breast, gastric, pancreatic, pulmonary, oesophageal and pharyngeal cancers and from cholangiocarcinoma and melanoma.
  • In 90 cases, we obtained a decrease in specific tumour marker level.
  • The technical success rate was 96%, and technical effectiveness estimated at 3 months after treatment was 83.6%.
  • [MeSH-major] Embolization, Therapeutic / methods. Liver Neoplasms / radiotherapy. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Dose-Response Relationship, Radiation. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Radiol. 2009 Apr;19(4):951-9 [18989675.001]
  • [Cites] J R Coll Surg Edinb. 1998 Jun;43(3):141-54 [9654872.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1975 Aug;124(4):596-9 [1163723.001]
  • [Cites] Cardiovasc Intervent Radiol. 2006 Jul-Aug;29(4):522-9 [16729228.001]
  • [Cites] Radiographics. 2008 Jan-Feb;28(1):81-99 [18203932.001]
  • [Cites] Cancer. 1967 May;20(5):793-804 [6024291.001]
  • [Cites] Cancer Biother Radiopharm. 2005 Apr;20(2):200-8 [15869456.001]
  • [Cites] Dis Colon Rectum. 1979 Sep;22(6):371-5 [498890.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):412-25 [16690429.001]
  • [Cites] In Vivo. 2006 Nov-Dec;20(6A):711-4 [17203751.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):800-4 [17524567.001]
  • [Cites] J Nucl Med. 2007 Dec;48(12):2080-6 [18006608.001]
  • [Cites] Arch Surg. 1964 Aug;89:244-9 [14160151.001]
  • [Cites] J Surg Res. 1983 Jan;34(1):17-24 [6823100.001]
  • [Cites] J Surg Oncol. 1989 Nov;42(3):192-6 [2811384.001]
  • [Cites] Radiology. 1982 Mar;142(3):783-6 [7063703.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Ann Surg. 1999 Jul;230(1):1-8 [10400029.001]
  • [Cites] Ann Surg. 1965 Aug;162:267-78 [14327011.001]
  • [Cites] Jpn J Clin Oncol. 2003 Oct;33(10):533-7 [14623923.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1975 Aug;124(4):590-5 [1163722.001]
  • [Cites] J Vasc Interv Radiol. 2008 May;19(5):683-90 [18440456.001]
  • [Cites] Eur Radiol. 2008 Sep;18(9):1937-52 [18446344.001]
  • [Cites] J Surg Oncol. 1978;10(4):327-36 [692139.001]
  • [Cites] J Vasc Interv Radiol. 2006 Sep;17(9):1425-39 [16990462.001]
  • [Cites] Am J Pathol. 1954 Sep-Oct;30(5):969-77 [13197542.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] Radiology. 2008 May;247(2):507-15 [18349311.001]
  • [Cites] Ann Surg. 1963 Jan;157:97-114 [13949718.001]
  • [Cites] J Vasc Interv Radiol. 2008 Aug;19(8):1187-95 [18656012.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1209-14 [15051767.001]
  • [Cites] ANZ J Surg. 2006 Aug;76(8):696-703 [16916386.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):778-87 [15772860.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2211-9 [11596040.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):918-28 [2990661.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):810-21 [12095546.001]
  • [Cites] J Vasc Interv Radiol. 2005 Aug;16(8):1101-6 [16105922.001]
  • [Cites] Future Oncol. 2007 Feb;3(1):73-81 [17280504.001]
  • (PMID = 20091135.001).
  • [ISSN] 1826-6983
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Yttrium Radioisotopes
  •  go-up   go-down


24. Zhi K, Ren W, Zhou H, Wen Y, Zhang Y: Management of parapharyngeal-space tumors. J Oral Maxillofac Surg; 2009 Jun;67(6):1239-44
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All cases were evaluated with at least a computed tomography scan.
  • The most common class of lesion was salivary-gland neoplasm, accounting for 74 cases (45.68%).
  • Only 22 patients (13.58%) presented with malignant disease.
  • Twenty patients with malignant disease underwent adjuvant chemotherapy and/or radiotherapy.
  • Two patients suffered local failure, and 4 patients developed distant metastasis during the observation period.
  • CONCLUSIONS: Surgery is the mainstay treatment for PPS tumors.
  • Surgical approaches were dictated by size of the tumor, its location, its relationship to the great vessels, and suspicion of malignancy.
  • [MeSH-major] Head and Neck Neoplasms / surgery. Pharyngeal Neoplasms / surgery
  • [MeSH-minor] Adenoma, Pleomorphic / surgery. Adult. Biopsy, Fine-Needle. Carcinoma / secondary. Carcinoma / surgery. Chemotherapy, Adjuvant. Cranial Nerve Diseases / etiology. Female. Follow-Up Studies. Humans. Magnetic Resonance Angiography. Magnetic Resonance Imaging. Male. Neck Muscles / surgery. Neoplasm Recurrence, Local / pathology. Parotid Gland / surgery. Postoperative Complications. Radiotherapy, Adjuvant. Retrospective Studies. Salivary Gland Neoplasms / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Oral Maxillofac Surg. 2010 May;68(5):1209-11; author reply 1212 [20403530.001]
  • (PMID = 19446210.001).
  • [ISSN] 1531-5053
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Ord RA, Blanchaert RH Jr: Current management of oral cancer. A multidisciplinary approach. J Am Dent Assoc; 2001 Nov;132 Suppl:19S-23S
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current management of oral cancer. A multidisciplinary approach.
  • BACKGROUND: Recent basic science discoveries have contributed to our understanding of the etiology of oral cancer and allowed us to consider innovative approaches to therapy.
  • METHODS: The authors evaluated and summarized current approaches to the management of oral cancer, emphasizing the multidisciplinary team approach to coordinate surgery, radiation therapy and chemotherapy.
  • Current concepts in management, including complications of therapy, are described.
  • RESULTS: State-of-the-art surgical techniques can spare patients with oral cancer from much of the morbidity and complications common in the past.
  • The refinement of treatment strategies reduces complications and improves efficacy.
  • Many exciting new clinical trials in the areas of gene therapy and immunomodulation are showing promise.
  • CONCLUSIONS: Management of oral cancer has undergone radical change in the past 10 years and continues to evolve rapidly.
  • Discoveries in molecular biology, diagnosis, surgery, radiation therapy and medical oncology have altered many traditional concepts and practices.
  • CLINICAL IMPLICATIONS: General dental practitioners need to understand current treatment modalities for oral and pharyngeal cancers to determine to whom they should refer patients for the most appropriate treatment, and to make recommendations regarding complications associated with these cancers.
  • [MeSH-major] Mouth Neoplasms / therapy
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / surgery. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Combined Modality Therapy. Comprehensive Dental Care. Genetic Therapy. Humans. Immunotherapy. Neoadjuvant Therapy. Patient Care Team. Radiotherapy Dosage. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Dent Assoc. 2002 Apr;133(4):410, 412; author reply 412 [11991452.001]
  • (PMID = 11803648.001).
  • [ISSN] 0002-8177
  • [Journal-full-title] Journal of the American Dental Association (1939)
  • [ISO-abbreviation] J Am Dent Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic
  •  go-up   go-down


26. Gallo A, Suriano M, Simonelli M, Ralli G, de Vincentiis M: Recurrent malignant schwannoma of the parapharyngeal space in neurofibromatosis type 1. Ear Nose Throat J; 2003 Nov;82(11):862-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent malignant schwannoma of the parapharyngeal space in neurofibromatosis type 1.
  • Malignant schwannoma is an aggressive tumor that carries a poor prognosis despite wide excision, chemotherapy, and radiotherapy.
  • Malignant schwannoma of the parapharyngeal space is an uncommon finding; to our knowledge, only four cases have been described in the literature during the past 30 years, and only one of them involved a patient who had clinical evidence of neurofibromatosis type 1.
  • In this article, we describe a new case of malignant schwannoma of the parapharyngeal space in a patient who had clinical evidence of neurofibromatosis type 1.
  • Following resection of the tumor and a total parotidectomy, the diagnosis was made on the basis of histology and immunohistochemistry.
  • The patient underwent postoperative chemotherapy with carboplatin and UP16.
  • However, 5 months following surgery, the tumor recurred and metastasized.
  • The IVA2 regimen slowed tumor growth, but 13 months after the initiation of therapy, the patient died of neoplastic cachexia.
  • Although chemotherapy is generally ineffective in most cases of malignant schwannoma, we did experience some positive results with the IVA2 protocol.
  • Therefore, we recommend that this combination be considered as a first-line adjuvant therapy following surgery or as a first-line therapy for patients with inoperable tumors.
  • [MeSH-major] Neurilemmoma / complications. Neurilemmoma / pathology. Neurofibromatosis 1 / complications. Pharyngeal Neoplasms / complications. Pharyngeal Neoplasms / pathology
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local


27. Genden EM, Kaufman MR, Katz B, Vine A, Urken ML: Tubed gastro-omental free flap for pharyngoesophageal reconstruction. Arch Otolaryngol Head Neck Surg; 2001 Jul;127(7):847-53
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Malignant lesions of the pharyngoesophagus often require total laryngopharyngectomy and mediastinal dissection.
  • As a result of the current treatment paradigms for advanced laryngopharyngeal cancers, it is common that the surgical field has been previously irradiated or exposed to systemic chemotherapy, resulting in fistula rates as high as 78% and mortality as high as 8%.
  • OBJECTIVE: To assess the gastro-omental free flap as a method of pharyngoesophageal reconstruction in patients who have been previously treated with multimodality therapy.
  • Five patients had received previous external beam irradiation, 2 had received systemic chemotherapy, and 4 had undergone previous surgery.
  • CONCLUSION: The tubed gastro-omental free flap offers a safe method of reconstructing the pharyngoesophageal segment in a surgical field compromised by previous multimodality therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods. Fibrosarcoma / surgery. Laryngectomy / methods. Liposarcoma / surgery. Pharyngeal Neoplasms / surgery. Pharyngectomy / methods. Surgical Flaps
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Postoperative Complications / etiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11448362.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Cappell MS: Risk factors and risk reduction of malignant seeding of the percutaneous endoscopic gastrostomy track from pharyngoesophageal malignancy: a review of all 44 known reported cases. Am J Gastroenterol; 2007 Jun;102(6):1307-11
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors and risk reduction of malignant seeding of the percutaneous endoscopic gastrostomy track from pharyngoesophageal malignancy: a review of all 44 known reported cases.
  • Mean survival after diagnosis was only 4.3+/-3.8 months.
  • Pathologic risk factors for stomal metastases included: (a) pharyngoesophageal location of primary cancer (in 100% of cases, 0% other locations);.
  • (d) advanced pathologic stage (in 97%, early stage in 3%); and (e) large primary cancer size at diagnosis (mean diameter 4.2+/-2.3 cm).
  • Therapeutic risk factors for stomal metastases included: (a) endoscopic PEG placement (in 98%, surgical gastrostomy in 2%);.
  • (c) primary cancer untreated or known local recurrence after treatment before PEG (in 87%); and (d) time>or=3 months after PEG insertion (in 100%, <3 months in 0%; mean interval 7.8+/-5.2 months after PEG).
  • Four of the currently reported risk factors are novel (pathologic factors d,e; therapeutic factors a,d).
  • CONCLUSIONS: Strong risk factors for stomal metastases include: pharyngoesophageal primary cancer, squamous cell histology, less well-differentiated cancer, large size, and advanced cancer stage.
  • The risk may be reduced in patients with risk factors by radiotherapy, chemotherapy, or cancer surgery before PEG; by substituting the push-guidewire for the pull-string technique for PEG; and possibly by use of a sheath with the pull-string technique.
  • [MeSH-major] Endoscopy, Gastrointestinal / adverse effects. Esophageal Neoplasms / pathology. Gastrostomy / adverse effects. Neoplasm Seeding. Pharyngeal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488255.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Oh WS, Roumanas E, Beumer J 3rd: Maxillofacial restoration after head and neck tumor therapy. Compend Contin Educ Dent; 2007 Feb;28(2):70-6; quiz 77, 101
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maxillofacial restoration after head and neck tumor therapy.
  • Oral and pharyngeal cancers are among the leading cancer sites.
  • Surgery, radiation, chemotherapy, or combination therapies are common treatment modalities.
  • Radiotherapy and chemotherapy cause significant morbidity and long-term irreversible sequelae in the oral cavity.
  • This article reviews current treatment modalities of tumor therapy, their consequences, and the restoration of maxillofacial defects.
  • [MeSH-minor] Cranial Irradiation / adverse effects. Dental Implants. Humans. Hyperbaric Oxygenation. Osteoradionecrosis / etiology. Osteoradionecrosis / therapy. Palatal Obturators. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17319178.001).
  • [ISSN] 1548-8578
  • [Journal-full-title] Compendium of continuing education in dentistry (Jamesburg, N.J. : 1995)
  • [ISO-abbreviation] Compend Contin Educ Dent
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dental Implants
  •  go-up   go-down


30. Simon C, Goepfert H, Rosenthal DI, Roberts D, El-Naggar A, Old M, Diaz EM Jr, Myers JN: Presence of malignant tumor cells in persistent neck disease after radiotherapy for advanced squamous cell carcinoma of the oropharynx is associated with poor survival. Eur Arch Otorhinolaryngol; 2006 Apr;263(4):313-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of malignant tumor cells in persistent neck disease after radiotherapy for advanced squamous cell carcinoma of the oropharynx is associated with poor survival.
  • Non-surgical therapy consisting of external beam radiation with or without chemotherapy is an effective treatment for patients with squamous cell carcinoma (SCC) of the oropharynx with advanced neck disease (N2a or greater).
  • It is reported that nearly 50% of the neck dissection specimens contain residual viable tumor cells that may indicate partial radiation failure and as a consequence poor survival.
  • In order to address the significance of this finding, we conducted a nonrandomized retrospective study, including 35 patients who underwent definitive radiation therapy followed by either a radical or modified radical (RND/MRND) or a selective neck dissection (SND) for clinically persistent neck disease 6 weeks after completing therapy for stage III/IV SCC of the oropharynx (base of the tongue =15, tonsil =12, soft palate =7 and pharyngeal wall =1).
  • All neck dissection specimens were reviewed according to histological criteria indicating viable residual tumor.
  • We observed an increased relative risk (RR) for local and regional failures in the patient population with viable cancer cells in the post-irradiation neck specimens (RR=6.7 and 4.1, respectively).
  • The presence of malignant tumor cells in residual disease in the neck correlated with poor disease-specific and overall survival (P =0.03 and P =0.01, respectively).
  • In conclusion, the presence of viable cancer cells in radiated neck nodes is a novel prognostic marker for disease-specific survival in patients treated for SCCs of the oropharynx with advanced neck disease and may serve as an identifier for patients who will benefit from post-treatment chemoprevention.
  • [MeSH-minor] Adult. Aged. Cell Survival. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck Dissection. Neoplasm, Residual. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(4):737-42 [1618666.001]
  • [Cites] Head Neck Surg. 1984 Jan-Feb;6(3):724-9 [6693288.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Mar;16(3):657-62 [2493434.001]
  • [Cites] Semin Radiat Oncol. 1992 Jul;2(3):163-170 [10717032.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jan 15;34(2):289-96 [8567328.001]
  • [Cites] Laryngoscope. 2000 Dec;110(12):2074-80 [11129024.001]
  • [Cites] Am J Surg. 1972 Oct;124(4):462-7 [5076159.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Head Neck. 2002 May;24(5):474-81 [12001078.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3964-71 [12351593.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Apr;124(4):401-6 [9559686.001]
  • [Cites] Head Neck. 2003 Nov;25(11):960-7 [14603457.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2967-80 [12115386.001]
  • [Cites] Head Neck. 1998 Mar;20(2):132-7 [9484944.001]
  • [Cites] CA Cancer J Clin. 2004 May-Jun;54(3):150-80 [15195789.001]
  • [Cites] Head Neck. 1999 Oct;21(7):606-13 [10487947.001]
  • (PMID = 16328403.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement